image credit: Adobe Stock

FDA delays decision on GSK bone cancer drug acquired in $2B buyout

June 16, 2023


Momelotinib was the main target in GSK’s nearly $2 billion purchase of Sierra Oncology last year, a gamble that the treatment will become a potential top seller despite competition from other medicines.

The drug, originally developed by biotechnology company Cytopia before changing hands multiple times, is meant to help reduce symptoms of myelofibrosis. The disease can cause a host of health problems, from anemia to fatigue, and those with anemia often need blood transfusions. Stem cell transplants can help some patients, while others are given medicines known as JAK inhibitors.

Read More on Biopharma Dive